ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has appointed Caesar J. Belbel, Executive Vice President, Chief Legal Officer and Secretary of the Company. In this position, Mr. Belbel will be responsible for the Company’s legal affairs and report to Richard Bagley, President, Chief Operating Officer, and Chief Financial Officer.
Mr. Belbel has served as a general counsel, transaction lawyer and senior executive for approximately 25 years. His expertise includes contractual matters; merger, acquisition and divestiture transactions; litigation management; corporate governance and regulatory compliance; and the discovery, establishment and enforcement of intellectual property rights. Since 2003, Mr. Belbel served as Executive Vice President, Chief Legal Officer and Secretary of Clinical Data, Inc., a biopharmaceutical company which was acquired in April 2011 by Forest Laboratories, Inc. Prior to joining Clinical Data, Mr. Belbel served as Senior Vice President, General Counsel and Secretary of Xpedior Incorporated, a publicly-held internet consulting services and e-commerce software development company. Mr. Belbel also served as General Counsel and Secretary for Programart Corporation, a developer of application performance management software, and Astea International Inc., a publicly-held developer and vendor of customer relationship management (CRM) application software. Mr. Belbel also has been a corporate partner in the emerging companies practice group of McDermott, Will & Emery. Mr. Belbel holds a Bachelor of Arts degree from Columbia University and a Juris Doctor from Boston College Law School.
“Caesar’s legal and strategic insight will be of enormous benefit as we develop our product candidate portfolio” stated Mr. Bagley. “Caesar is a highly accomplished corporate counselor and advisor whom we are pleased to welcome to the ZIOPHARM team.”
“The management team at ZIOPHARM has advanced, through thoughtful development strategies, a diversified and uniquely promising pipeline of oncology therapeutics,” said Mr. Belbel. “I look forward to working with the team at this important time in the Company’s development and to contributing to ZIOPHARM in its mission of developing better cancer medicines.”